Drug intelligence / Profile preview

rituximab + hyaluronidase human

Development stage: Approved
Lead developer: Genentech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Therapeutic Enzymes → Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

**Rituximab + hyaluronidase human** is a fixed-dose subcutaneous combination of rituximab, a CD20-directed cytolytic chimeric monoclonal antibody, and recombinant human hyaluronidase PH20. Rituximab depletes CD20-positive B cells through immune-mediated cytotoxic mechanisms, while hyaluronidase transiently degrades subcutaneous hyaluronan to promote tissue dispersion and absorption of rituximab. Marketed as Rituxan Hycela in the United States and MabThera SC in certain ex-US markets, it provides a faster subcutaneous alternative to intravenous rituximab after at least one full intravenous rituximab dose. It is approved for adult follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia.

Brand names: MabThera SCRituxan Hycela
Other names: rituximab + recombinant human hyaluronidaserituximab and hyaluronidase humanrituximab hyaluronidaserituximab/hyaluronidase human

Targets

CD20 (B-lymphocyte antigen CD20)

Beyond the preview

Go deeper on rituximab + hyaluronidase human.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rituximab + hyaluronidase human.

Explore the full profile